Aurinia Pharmaceuticals (AUPH) Research & Development (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Research & Development data on file, last reported at $7.5 million in Q1 2026.

• Quarterly Research & Development rose 30.07% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.2 million (up 63.19% YoY) and the FY2025 annual result came in at $32.5 million, up 56.39% from the prior year.
• Research & Development declined to $7.5 million in Q1 2026, from $10.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $13.6 million in Q3 2023 to a low of $3.0 million in Q3 2024.
• A 5-year average of $8.6 million and a median of $8.4 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development surged 228.95% — and 2024, when it slumped 77.6%.
• Tracing AUPH's Research & Development over 5 years: stood at $9.9 million in 2022, then gained by 3.63% to $10.2 million in 2023, then dropped by 20.74% to $8.1 million in 2024, then jumped by 34.39% to $10.9 million in 2025, then slumped by 31.44% to $7.5 million in 2026.
• The last three Research & Development figures came in at $7.5 million (Q1 2026), $10.9 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.